A practical reference on Cardarine: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-07-28 and is reviewed periodically as new material appears.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
| Property | Value | Notes |
|---|---|---|
| Solubility | Soluble in dimethyl sulfoxide and some organic solvents; practically insoluble in water | Solvent choice affects laboratory handling |
| Typical storage | -20 °C, desiccated, protected from light | Common condition for research samples |
| Analytical method | Liquid chromatography–tandem mass spectrometry (LC-MS/MS) | Used for identification and quantification in biological or product samples |
| Common synonyms | GW501516, GW-501516, GSK-516, Endurobol | Names found in research and anti-doping literature |
| Regulatory status | Unapproved therapeutic; prohibited in competitive sport | Status can vary by country and context |
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Berkelium-242 was synthesized in 1979 by bombarding 235U with 11B, 238U with 10B, 232Th with 14N or 232Th with 15N. It converts by electron capture to 242Cm with a half-life of 7.0±1.3 minutes. A search for an initially suspected isotope 241Bk was then unsuccessful; 241Bk has since been synthesized.
=== Drug interactions === Clinical drug-drug interactions with dalbavancin have not been studied, and dalbavancin does not appear to interact with cytochrome P450 substrates, inhibitors, or inducers. It was found to have an in vitro synergistic interaction with the antimicrobial oxacillin, but the clinical significance of this interaction has yet to be established.
=== Sequence data === Most of the work on substitution models has focused on DNA/RNA and protein sequence evolution. Models of DNA sequence evolution, where the alphabet corresponds to the four nucleotides (A, C, G, and T), are probably the easiest models to understand. DNA models can also be used to examine RNA virus evolution; this reflects the fact that RNA also has a four nucleotide alphabet (A, C, G, and U). However, substitution models can be used for alphabets of any size; the alphabet is the 20 proteinogenic amino acids for proteins and the sense codons (i.e., the 61 codons that encode amino acids in the standard genetic code) for aligned protein-coding gene sequences. In fact, substitution models can be developed for any biological characters that can be encoded using a specific alphabet (e.g., amino acid sequences combined with information about the conformation of those amino acids in three-dimensional protein structures). The majority of substitution models used for evolutionary research assume independence among sites (i.e., the probability of observing any specific site pattern is identical regardless of where the site pattern is in the sequence alignment). This simplifies likelihood calculations because it is only necessary to calculate the probability of all site patterns that appear in the alignment then use those values to calculate the overall likelihood of the alignment (e.g., the probability of three "GGGG" site patterns given some model of DNA sequence evolution is simply the probability of a single "GGGG" site pattern raised to the third power).
Sources: en.wikipedia.org
== Trial and imprisonment == Allitt had attacked 13 children, four fatally, over a 59-day period. It was only following the death of Becky Phillips that medical staff became suspicious of the number of cardiac arrests on the children's ward and police were called in. It was found that Allitt was the only nurse on duty for all the attacks on the children and had access to the drugs used. Four of Allitt's victims had died. She was charged with four counts of murder, eleven counts of attempted murder, and eleven counts of causing grievous bodily harm. Allitt entered pleas of not guilty to all charges. On 28 May 1993, she was found guilty on each charge and sentenced to 13 concurrent terms of life imprisonment, which she is serving at Rampton Secure Hospital in Nottinghamshire. On 6 December 2007, Mr Justice Stanley Burnton, sitting in the High Court of Justice, London, ordered Allitt to serve the original minimum sentence of 30 years. It was reported that some families of Allitt's victims had previously mistakenly believed that her minimum tariff had been set at 40 years. Her minimum tariff expired in November 2021 and she is now eligible for release on parole. Allitt's motives have never been fully explained. According to one theory, she showed symptoms of a factitious disorder also known as Munchausen syndrome by proxy. On 3 October 2023, it was reported that Allitt was appearing before a mental health tribunal to be assessed for a potential transfer to a mainstream prison. If the transfer takes place, Allitt will be eligible for parole after six months.
=== 2010–2012: Early career === Melksham was recruited by the Essendon Football Club with their first selection and tenth overall in the 2009 national draft. The Age journalist, Will Brodie, predicted he would debut and play in the midfield early in the season and he made his debut in the twenty point win against Carlton at the Melbourne Cricket Ground in round three. He played the next two matches before he was omitted for the round six match against Hawthorn at the Melbourne Cricket Ground; he returned the next week for the three-point loss against Port Adelaide at Etihad Stadium where he kicked his first AFL goal. He was rewarded with the round eight nomination in the AFL Rising Star after he recorded fourteen possessions, three clearances, three tackles and a goal in the twelve point win against St Kilda at Etihad Stadium. He missed the round ten match against the Western Bulldogs after he sprained his ankle during the thirty-five-point win against Richmond the week before, he returned the next week for the nine-point loss against Sydney at the Sydney Cricket Ground. He played the next four out of five matches, missing the round fifteen match against Melbourne due to being rested, before he was dropped for the round seventeen match against North Melbourne at Etihad Stadium.
Lidocaine, also known as lignocaine and sold under the brand name Xylocaine among others, is a local anesthetic of the amino amide type. It is also used to treat ventricular tachycardia and ventricular fibrillation. When used for local anaesthesia or in nerve blocks, lidocaine typically begins working within several minutes and lasts for half an hour to three hours. Lidocaine mixtures may also be applied directly to the skin or mucous membranes to numb the area. It is often used mixed with a small amount of adrenaline (epinephrine) to prolong its local effects and to decrease bleeding. If injected intravenously, it may cause cerebral effects such as confusion, changes in vision, numbness, tingling, and vomiting. It can cause low blood pressure and an irregular heart rate. There are concerns that injecting it into a joint can cause problems with the cartilage. It appears to be generally safe for use in pregnancy. A lower dose may be required in those with liver problems. It is generally safe to use in those allergic to tetracaine or benzocaine. Lidocaine is an antiarrhythmic medication of the class Ib type. This means it works by blocking sodium channels thus decreasing the rate of contractions of the heart. When injected near nerves, the nerves cannot conduct signals to or from the brain. Lidocaine was discovered in 1946 and went on sale in 1948. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication.
This is seen as the beginning of the second phase of the 1948 Palestine war. June 12: Mátyás Rákosi becomes General Secretary of the Hungarian Working People's Party and, therefore, the de facto leader of the Second Hungarian Republic. June 18: A communist insurgency in Malaya begins against British and Commonwealth forces. June 21: In Germany, the British zone and the French zone launch a common currency, the Deutsche Mark. June 24: Stalin orders the Berlin Blockade, closing all land routes from West Germany to Berlin, in an attempt to starve out the French, British, and American forces from the city. In response, the three Western powers launch the Berlin Airlift to supply the citizens of Berlin by air. June 28: The Soviet Union expels Yugoslavia from the Communist Information Bureau (COMINFORM) for the latter's position on the Greek Civil War. June 28: Stalin attempts to starve West Berlin with a blockade. The Berlin Airlift begins. August 1: French zone of occupation created in Germany and Berlin. August 15: The United States declares the Republic of Korea to be the legitimate government of the Korean Peninsula, with Syngman Rhee installed as the leader. September 9: The Soviet Union declares the Democratic People's Republic of Korea to be the legitimate government of all of the Korean Peninsula, with Kim Il Sung installed as the leader. September 11: Muhammad Ali Jinnah dies. September 13: India annexes Hyderabad under the code name, Operation Polo.
Sources: en.wikipedia.org
It binds and activates PPARδ, a nuclear receptor that influences gene expression related to fatty acid metabolism and energy balance. This mechanism has been studied mainly in animals and cell models, not established as a safe human therapy.
No. It is not an anabolic-androgenic steroid; it is a synthetic PPARδ agonist. Because it is banned in sport, it is sometimes grouped with doping agents even though its chemical class differs from steroids.
Human data are limited and development was discontinued, so major effects and long-term risks are not well characterized. Some early studies examined metabolic markers, but they do not provide a basis for unsupervised use.
Anti-doping laboratories typically use LC-MS/MS to detect GW501516 and its metabolites in urine. The method is sensitive and can identify the compound at low concentrations. Detection depends on sample timing, metabolism, and the specific assay.